Adalimumab for rheumatoid arthritis (Journal article)

Voulgari, P. V./ Drosos, A. A.


In the last few years significant advances have been made in our understanding of the molecular mechanisms underlying rheumatoid arthritis pathogenesis. Pro-inflammatory cytokines, such as TNF-alpha, play a pivotal role in its pathogenesis. Anti-TNF-alpha biological agents are considered a major advance in the treatment of rheumatoid arthritis. Adalimumab is a fully human monoclonal antibody that binds specifically to TNF-alpha, thereby neutralising its activity. It had significant efficacy in well-designed, placebo-controlled trials in patients suffering from rheumatoid arthritis, both as monotherapy and in combination with various disease-modifying antirheumatic drugs, including methotrexate. Adalimumab was generally well tolerated during both concomitant therapy with methotrexate or standard antirheumatic therapy and monotherapy. In addition, the radiographic progression of structural joint damage was significantly inhibited by adalimumab and improved quality of life. This review summarises the recent available data.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Animals,Antibodies, Monoclonal/pharmacology/*therapeutic use,Antibodies, Monoclonal, Humanized,Antirheumatic Agents/pharmacology/therapeutic use,Arthritis, Rheumatoid/immunology/metabolism/*therapy,Humans,Tumor Necrosis Factor-alpha/antagonists & inhibitors/immunology
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/24070
ISSN: 1744-7682
Link: http://www.ncbi.nlm.nih.gov/pubmed/17223742
http://informahealthcare.com/doi/abs/10.1517/14712598.6.12.1349
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/24070
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.